BLyS/APRIL西

Jingjing Jin1,2, Meng Tan1, Ying Tan1

  • 1Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, PR China.

概括

与标准治疗相比,Telitacicept在狼性炎患者中显著改善了反应. 这种治疗显示出良好的安全性,特别是在V型狼性炎和显著蛋白尿症患者中.